DFX Intelligence

Data Factory

Private equityFirmprivate credit · probablemiddle market

Pharmakon Advisors, LP

Private Equity

New York, NY

Pharmakon Advisors, LP is a leading investment management firm specializing in providing strategic financing solutions to the life sciences industry.

This is the graph view. The full profile, with its team, deals and sources, is on Private Equity.Open the full profile →

Search this name across graphsid dfx:pe:a10b803b-76a9-4cbe-be4d-9bda92124c67

Data as of Sep 15, 2026 (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built Sep 19, 2026, 1:57 PM UTC and rebuilt at most every 15 minutes.

Relationships: 20
Dated events: 21
On other graphs: 3
Observed: Sep 13, 2026 to Sep 15, 2026
30 observations

Across DFX

same identity by shared identifier, citation, or a bridge measured by hand

Independent Sponsorsidentity

Pharmakon Advisors, LP

Capital provider to sponsors · shared crd

RIA / Wealth Managementidentity

PHARMAKON ADVISORS, LP

Registered adviser · shared crd

Private Creditidentity

Pharmakon Advisors, LP

Private credit manager · shared crd

Facts

fact = as filed or announced; derived = computed by DFX; estimate = a band, never a point

Funds: 9
PE funds: 9
Vintages: 2014 to 2020
PE GAV, 2024 filing: $1.8Bgross asset value on Form ADV; never dry powder
Regulatory AUM: $3.1B
Investments: 0
Active investments: 0
Size band: MIDDLE MARKETderivedproxy: $1.82bn Private Equity Fund GAV on the Form ADV filed 2024-04-12
Stated sectors: healthcare,life_sciences
Latest ADV filing: Apr 12, 2024
Employees (ADV): 12
Website: pharmakonadvisors.com

Funds

Fund	Vintage	Lifecycle	ADV type	Form D sold	GAV
Biopharma Credit Investments V (master) LP	2020	Active deployment	Private Equity Fund	n/a	$1.8B
Pharmakon Opportunities LP	2019	Wound down	Private Equity Fund	n/a	$46.5M
Biopharma Secured Investments III Partners, LP	2018	Wound down	Private Equity Fund	n/a	$11.8M
Biopharma Secured Investments III (cayman) Feeder LP	2018	Wound down	Private Equity Fund	n/a	$5.4M
Biopharma Secured Investments III Holdings Cayman LP	2018	Wound down	Private Equity Fund	n/a	$16.7M
Biopharma Credit Investments IV, Sarl	2016	Wound down	Private Equity Fund	n/a	$0
Biopharma Secured Investments III Sarl	2014	Wound down	Private Equity Fund	n/a	$345M
Biopharma Secured Debt Fund, LP	n/a	Wound down	Private Equity Fund	n/a	$29.9M
Biopharma Secured Debt Fund II, Sarl	n/a	Wound down	Private Equity Fund	n/a	$138M

Relationships

Employs (8)

→ Pedro Gonzalez de CosioPersonCo-Founder, Principal and CEO
factThe subject's own site
→ Patrick FisherPersonVice President (Investor Relations)
factThe subject's own site
→ Douglas Yeon KimPersonChief Compliance Officer
Sep 1, 2022 to presentfactForm ADV, The subject's own site
→ Scott LevittPersonVice President
factThe subject's own site
→ Martin G FriedmanPersonLimited Partner
Jan 1, 2013 to presentfactForm ADV
→ Pablo Gerardo LegorretaPersonManaging Member
Apr 1, 2009 to presentfactForm ADV
→ Pedro GonzalezdecosioPersonManaging Member
Apr 1, 2009 to presentfactForm ADV
→ Benjamin Claas SchliemannPersonManaging Member
Apr 1, 2009 to Mar 31, 2014inferenceForm ADV

Firm member (1)

→ RpFirmadviser
factDFX's own graph

Manages (9)

→ Biopharma Credit Investments V (master) LPFundPrivate Equity Fund
Mar 27, 2020 to presentfactForm ADV
→ Biopharma Secured Debt Fund, LPFundPrivate Equity Fund
Feb 15, 2012 to presentfactForm ADV
→ Biopharma Secured Debt Fund II, SarlFundPrivate Equity Fund
Feb 15, 2012 to presentfactForm ADV
→ Biopharma Secured Investments III SarlFundPrivate Equity Fund
Mar 31, 2014 to presentfactForm ADV
→ Biopharma Credit Investments IV, SarlFundPrivate Equity Fund
Mar 29, 2016 to presentfactForm ADV
→ Biopharma Secured Investments III Holdings Cayman LPFundPrivate Equity Fund
Mar 29, 2018 to presentfactForm ADV
→ Biopharma Secured Investments III (cayman) Feeder LPFundPrivate Equity Fund
Mar 29, 2018 to presentfactForm ADV
→ Biopharma Secured Investments III Partners, LPFundPrivate Equity Fund
Mar 29, 2018 to presentfactForm ADV
→ Pharmakon Opportunities LPFundPrivate Equity Fund
Mar 29, 2019 to presentfactForm ADV

Owns (1)

← Pharmakon Management I LLCFirmGeneral Partner
Apr 1, 2009 to presentfactForm ADV

Dated events

17 bookkeeping events (roster, classification and holdings changes) folded below

Occurred
Sep 1, 2022
Person joined
Douglas Yeon Kim joined Schedule A of Pharmakon Advisors, LP as Chief Compliance Officer
Form ADVobserved 5 days ago
Occurred
Mar 31, 2014
Person left
Benjamin Claas Schliemann (Managing Member) no longer on Schedule A of Pharmakon Advisors, LP
Form ADVobserved 5 days ago
Occurred
Jan 1, 2013
Person joined
Martin G Friedman joined Schedule A of Pharmakon Advisors, LP as Managing Member
Form ADVobserved 5 days ago
Occurred
Feb 15, 2012
Adviser first adv filing
Pharmakon Advisors, LP first filed Form ADV in the extract (IA)
Form ADVobserved 5 days ago

Show 17 bookkeeping events

Occurred
Mar 28, 2024
Fund 805-5312474673 no longer reported on Form ADV by Pharmakon Advisors, LP
Occurred
Mar 27, 2020
Fund 805-4802502769 no longer reported on Form ADV by Pharmakon Advisors, LP
Occurred
Mar 27, 2020
Fund 805-8622676619 no longer reported on Form ADV by Pharmakon Advisors, LP
Occurred
Mar 27, 2020
Fund 805-7826269271 no longer reported on Form ADV by Pharmakon Advisors, LP
Occurred
Mar 27, 2020
Fund 805-9845900807 no longer reported on Form ADV by Pharmakon Advisors, LP
Occurred
Mar 27, 2020
Biopharma Credit Investments V (master) LP first reported on Form ADV by Pharmakon Advisors, LP (Private Equity Fund), GAV $200,439,455
Occurred
Mar 29, 2019
Pharmakon Opportunities LP first reported on Form ADV by Pharmakon Advisors, LP (Private Equity Fund), GAV $46,472,032
Occurred
Mar 29, 2018
Biopharma Secured Investments III Holdings Cayman LP first reported on Form ADV by Pharmakon Advisors, LP (Private Equity Fund), GAV $267,711,988
Occurred
Mar 29, 2018
Fund 805-1253180070 no longer reported on Form ADV by Pharmakon Advisors, LP
Occurred
Mar 29, 2018
Fund 805-3130153519 no longer reported on Form ADV by Pharmakon Advisors, LP
Occurred
Mar 29, 2018
Biopharma Secured Investments III Partners, LP first reported on Form ADV by Pharmakon Advisors, LP (Private Equity Fund), GAV $146,882,660
Occurred
Mar 29, 2018
Biopharma Secured Investments III (cayman) Feeder LP first reported on Form ADV by Pharmakon Advisors, LP (Private Equity Fund), GAV $56,185,598
Occurred
Mar 29, 2016
Biopharma Credit Investments IV, Sarl first reported on Form ADV by Pharmakon Advisors, LP (Private Equity Fund), GAV $292,174,549
Occurred
Mar 31, 2015
Fund 805-5363562642 no longer reported on Form ADV by Pharmakon Advisors, LP
Occurred
Mar 31, 2014
Biopharma Secured Investments III Sarl first reported on Form ADV by Pharmakon Advisors, LP (Private Equity Fund), GAV $498,689,579
Occurred
Feb 15, 2012
Biopharma Secured Debt Fund, LP first reported on Form ADV by Pharmakon Advisors, LP (Private Equity Fund), GAV $121,282,177
Occurred
Feb 15, 2012
Biopharma Secured Debt Fund II, Sarl first reported on Form ADV by Pharmakon Advisors, LP (Private Equity Fund), GAV $363,100,000

Who to call

the organisation, the role and the published line, with the filing or website that published it; revealed to signed-in accounts

The firm's published line

Revealable: 1 business phone (Form ADV), 1 office address (Form ADV), 1 website (Form ADV) · as of 2026-09-13

Also named here, with no published line of their own (reach them through the firm): Pedro Gonzalez de Cosio (Co-Founder, Principal and CEO), Patrick Fisher (Vice President (Investor Relations)), Douglas Yeon Kim (Chief Compliance Officer), Scott Levitt (Vice President), Martin G Friedman (Limited Partner), Pablo Gerardo Legorreta (Managing Member), Pedro Gonzalezdecosio (Managing Member).

Who to call is the organisation, the person's role and the line they published themselves: a business phone, office address, website or profile link from Form ADV, Form 13F or their own website, with that source named on every value. The counts above are what a reveal returns; a personal email is rarely published, so most reveals are the firm's line. Never data bought from a provider, never anything personal. Reveals by plan

Provenance

Graph: Private Equity
Canonical id: dfx:pe:a10b803b-76a9-4cbe-be4d-9bda92124c67
First observed: Sep 13, 2026
Last observed: Sep 15, 2026 3 days ago
Source families: Federal regulator filings, Firm and issuer disclosures
3 registered feeds stand behind this record; each fact above carries its own dates and, where the publisher serves one, its document.
Resolution: Identity across graphs by shared identifier (CRD, CIK, EIN, ADV fund id, individual CRD) or citation; a name match is shown as a candidate and never merged.

Pharmakon Advisors, LP

Private Equity

New York, NY

Pharmakon Advisors, LP is a leading investment management firm specializing in providing strategic financing solutions to the life sciences industry.

This is the graph view. The full profile, with its team, deals and sources, is on Private Equity.Open the full profile →

Search this name across graphsid dfx:pe:a10b803b-76a9-4cbe-be4d-9bda92124c67

Data as of Sep 15, 2026 (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built Sep 19, 2026, 1:57 PM UTC and rebuilt at most every 15 minutes.

Fund

Vintage

Lifecycle

ADV type

Form D sold

GAV

LPs

Biopharma Credit Investments V (master) LP

2020

Active deployment

Private Equity Fund

n/a

$1.8B

Pharmakon Opportunities LP

2019

Wound down

Private Equity Fund

n/a

$46.5M

Biopharma Secured Investments III Partners, LP

2018

Wound down

Private Equity Fund

n/a

$11.8M

Biopharma Secured Investments III (cayman) Feeder LP

2018

Wound down

Private Equity Fund

n/a

$5.4M

Biopharma Secured Investments III Holdings Cayman LP

2018

Wound down

Private Equity Fund

n/a

$16.7M

Biopharma Credit Investments IV, Sarl

2016

Wound down

Private Equity Fund

n/a

Biopharma Secured Investments III Sarl

2014

Wound down

Private Equity Fund

n/a

$345M

Biopharma Secured Debt Fund, LP

n/a

Wound down

Private Equity Fund

n/a

$29.9M

Biopharma Secured Debt Fund II, Sarl

n/a

Wound down

Private Equity Fund

n/a

$138M